Emergency department visits for childhood wheezing represent a critical intervention point where effective treatments could prevent respiratory complications and reduce healthcare burden. A significant portion of these episodes may have infectious triggers, making antibiotic intervention theoretically appealing for clinicians seeking to address both bacterial and potential atypical pathogen involvement.
This randomized controlled trial examined azithromycin's effectiveness in 394 preschool children presenting to emergency departments with acute wheezing episodes. The macrolide antibiotic, known for both antimicrobial and anti-inflammatory properties, showed no significant improvement in clinical outcomes compared to placebo. Children receiving azithromycin demonstrated similar rates of treatment failure, hospital admissions, and symptom resolution timelines as those receiving standard care alone.
The findings challenge a common clinical practice where antibiotics are sometimes prescribed for wheezing episodes, particularly when viral versus bacterial etiology remains unclear. This represents important evidence against routine antibiotic use in pediatric wheezing, supporting current guidelines that emphasize bronchodilators and corticosteroids as primary interventions. The study's emergency department setting makes results particularly relevant for acute care decision-making, where time pressure often influences treatment choices. For antimicrobial stewardship efforts, this adds substantial evidence that azithromycin's anti-inflammatory effects do not translate to meaningful clinical benefits in this population. The research reinforces that most preschool wheezing episodes are viral-mediated and self-limiting, requiring supportive care rather than antimicrobial intervention, potentially reducing unnecessary antibiotic exposure and associated resistance development.